New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
09:06 EDTMACKMerrimack announces positive clinical data for agent to treat breast cancer
Merrimack announced Phase I clinical trial results for MM-302, the company's agent for the treatment of advanced HER2 positive breast cancer. The findings demonstrated preliminary safety and tolerability.
News For MACK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
05:20 EDTMACKPharmaEngine, Merrimack receive FDA fast track designation for MM-398
PharmaEngine and its partner Merrimack Pharmaceuticals (MACK) announced that MM-398 has been granted the Fast Track designation by the FDA for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. Merrimack expects to begin the NDA submission in 2014.
November 19, 2014
09:16 EDTMACKOn The Fly: Pre-market Movers
Subscribe for More Information
08:07 EDTMACKMerrimack receives FDA fast track designation for MM-398
Subscribe for More Information
November 18, 2014
07:20 EDTMACKEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 13, 2014
09:15 EDTMACKMerrimack to present advances on targeted cancer molecules
Merrimack Pharmaceuticals announced that it will present research on three of its therapeutic candidates at the 2014 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 18-21. Data will be shared in four poster sessions. Presentations will include results from a clinical study using ferumoxytol as a magnetic resonance imaging agent and its ability to predict tumor response to MM-398, preclinical and clinical research on MM-151 and an initial preclinical study of MM-131, a novel bispecific antibody targeting the c-Met tumor signaling pathway.
November 11, 2014
08:05 EDTMACKMerrimack shares should be bought on weakness, says Oppenheimer
After Merrimack announced a delay of about one quarter for the NDA submission of its MM-398, Oppenheimer's concern about the issue is limited. The firm says that the FDA appears to be interested in ensuring that MM-398 has extended nanoparticle stability, but does not appear to have identified a material deficit in the company's chemistry, manufacturing, and controls. Oppenheimer keeps an $11 price target and Outperform rating on Merrimack.
November 10, 2014
16:09 EDTMACKMerrimack reports Q3 EPS (27c), consensus (12c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use